Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
https://clinicaltrials.gov/study/NCT07209410
Sponsor: Insight Eyecare Specialties, Inc dba Vision Source Eyecare
Purpose: To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering. Phase 4.
Enrollment: 35
Information: drremington@vseyecare.com
Topical Insulin for Glaucoma
https://clinicaltrials.gov/study/NCT05206877
Sponsor: Stanford University
Purpose: The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen). Phase 1.
Enrollment: 52
Information: mnunez1@stanford.edu
Phase 2 Study of BL1107 Eye Drops vs Timolol in Adults With Primary Open-Angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/study/NCT07168902
Sponsor: Bausch + Lomb Inc.
Purpose: To evaluate the safety and efficacy of BL1107, compared with timolol 0.5%, in adults with primary open-angle glaucoma or ocular hypertension in both eyes. Phase 2.
Enrollment: 228
Information: Johnson.Varughese@bausch.com
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
https://clinicaltrials.gov/study/NCT04577300
Sponsor: Stanford University
Purpose: To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma. Phase 2.
Enrollment: 30
Information: Byers Eye Institute
Retinal Blood Flow and Autoregulation
https://clinicaltrials.gov/study/NCT05344274
Sponsor: University of Maryland, Baltimore
Purpose: The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma. Phase 4.
Enrollment: 90
Information: osaeedi@som.umaryland.edu
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open-Angle Glaucoma
https://clinicaltrials.gov/study/NCT07228221
Sponsor: Glaukos Corporation
Purpose The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma. Phase 4.
Enrollment: 20
Information: mdivers@willseye.org
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
https://clinicaltrials.gov/study/NCT02862938
Sponsor: Stanford University
Purpose: To determine the efficacy of NT-501 encapsulated cell therapy implant in patients with glaucoma as measured by change in visual field through 6 months. Phase 2.
Enrollment: 60
Information: Byers Eye Institute
Phase 2/3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
https://clinicaltrials.gov/study/NCT07075718
Sponsor: Glaukos
Purpose: Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant. Phase 2/3.
Enrollment: 610
Information: idoseclinical@glaukos.com
Pilocarpine Use After Kahook Goniotomy
https://clinicaltrials.gov/study/NCT03933631
Sponsor: Montefiore Medical Center
Purpose: To determine whether using pilocarpine provides added benefit to the success of combined cataract + Kahook Dual Blade (KDB) surgery. Phase 3
Enrollment: 142
Information: WYAO@montefiore.org
A Study of PER-001 in Participants With Open-Angle Glaucoma
https://clinicaltrials.gov/study/NCT05822245
Sponsor: Perfuse Therapeutics, Inc.
Purpose: To evaluate safety, tolerability, and pharmacodynamic effect after single administration of PER-001 intravitreal implant in participants with open-angle glaucoma. Phase 1/2a.
Enrollment: 36
Information:
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation
https://clinicaltrials.gov/study/NCT05411198
Sponsor: AbbVie
Purpose: This phase 3 study will assess how safe and effective the Xen gel stent is when implanted using the ab externo approach in patients aged 45 years or older with open-angle glaucoma. Phase 3.
Enrollment: 65
Information: abbvieclinicaltrials@abbvie.com
Efficacy and Safety Assessment of T4090 Ophthalmic Solution vs Rhopressa Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/study/NCT06394973
Sponsor: Laboratoires Thea
Purpose: To compare the ocular hypotensive efficacy and safety of 2 concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa ophthalmic solution. Phase 2.
Enrollment: 126
Information:
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
https://clinicaltrials.gov/study/NCT06883123
Sponsor: Prairie Eye Center
Purpose: A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month. Phase 4.
Enrollment: 70
Information: jenniferlyons37@gmail.com
Use of Methazolamide to Lower Intraocular Pressure
https://clinicaltrials.gov/study/NCT05498103
Sponsor: University of Colorado, Denver
Purpose: To evaluate the effect of methazolamide 25 mg or 50 mg tablets once a day for a week, then twice a day for a week, on lowering intraocular pressure, and the safety of methazolamide. Phase 4.
Enrollment: 30
Information: Sue Anschutz-Rodgers Eye Center
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
https://clinicaltrials.gov/study/NCT06822738
Sponsor: AbbVie
Purpose: This phase 3 study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab externo (outside the eye) approach. Adverse events and intraocular pressure will be assessed. Phase 3.
Enrollment: 130
Information: abbvieclinicaltrials@abbvie.com
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
https://clinicaltrials.gov/study/NCT05695027
Sponsor: Stanford University
Purpose: To determine if a combination of oral nicotinamide and pyruvate (N&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. Phase 2/3.
Enrollment: 250
Information:
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients
https://clinicaltrials.gov/study/NCT05389267
Sponsor: Laboratoires Thea
Purpose: To evaluate the safety of T4090. Phase 1/2.
Enrollment: 120
Information:
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
https://clinicaltrials.gov/study/NCT06223048
Sponsor: Amydis Inc.
Purpose: To assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG). Phase 2.
Enrollment: 50
Information: joyce@amydis.com
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/study/NCT04499248
Sponsor: AbbVie
Purpose: This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension. Phase 1/2.
Enrollment: 96
Information: abbvieclinicaltrials@abbvie.com
Clarifying the Optimal Application of SLT Therapy Trial (COAST)
https://clinicaltrials.gov/study/NCT04967989
Sponsor: National Eye Institute/West Virginia University
Purpose: To understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it. Phase 3.
Enrollment: 790
Information: hypotonywvu@gmail.com
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
https://clinicaltrials.gov/study/NCT07218796
Sponsor: SpyGlass Pharma, Inc.
Purpose: This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. Phase 3.
Enrollment: 400
Information: clinical@spyglasspharma.com
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
https://clinicaltrials.gov/study/NCT07218783
Sponsor: SpyGlass Pharma, Inc.
Purpose: To evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. Phase 3.
Enrollment: 400
Information: clinical@spyglasspharma.com
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
https://clinicaltrials.gov/study/NCT06964191
Sponsor: PolyActiva Pty Ltd
Purpose: To determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy. Phase 2.
Enrollment: 75
Information: vanessa.waddell@polyactiva.com
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
https://clinicaltrials.gov/study/NCT06120842
Sponsor: SpyGlass Pharma, Inc.
Purpose: A randomized study to evaluate and compare 2 doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. Phase 1/2.
Enrollment: 201
Information:
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and Lumigan in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes
https://clinicaltrials.gov/study/NCT05401357
Sponsor: Amneal Pharmaceuticals, LLC
Purpose: To demonstrate bioequivalence between the test product (bimatoprost ophthalmic solution, 0.01%) and the reference product (bimatoprost ophthalmic solution, 0.01% [Lumigan/Allergan]) with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Phase 3
Enrollment: 168
Information: ilesh@amnealindia.com
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
https://clinicaltrials.gov/study/NCT06267274
Sponsor: Amneal Pharmaceuticals, LLC
Purpose: A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study. Phase 1.
Enrollment: 240
Information: ilesh@amneal.com
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
https://clinicaltrials.gov/study/NCT03891446
Sponsor: AbbVie
Purpose: This study will evaluate the long-term safety and efficacy of bimatoprost sustained release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 phase 3 bimatoprost SR studies and received bimatoprost SR or who received commercial Durysta (bimatoprost SR; ) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study. Phase 3.
Enrollment: 455
Information:
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
https://clinicaltrials.gov/study/NCT07082816
Sponsor: Alcon Research
Purpose: This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT). Phase 3.
Enrollment: 470
Information: alcon.medinfo@alcon.com
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
https://clinicaltrials.gov/study/NCT06865144
Sponsor: East Coast Institute for Research
Purpose: To collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes. Phase 4.
Enrollment: 70
Information: rg@eastcoastresearch.net
Safety and Efficacy of iDose TR With Cataract Surgery vs Cataract Surgery Alone
https://clinicaltrials.gov/study/NCT06848946
Sponsor: Glaukos Corporation
Purpose: To evaluate the safety and IOP-lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone. Phase 4.
Enrollment: 132
Information: ClinicalResearch@glaukos.com
Outcomes Mandate National Integration With Cannabis as Medicine
https://clinicaltrials.gov/study/NCT03944447
Sponsor: OMNI Medical Services Inc
Purpose: Multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions. Phase 2.
Enrollment: 200,000
Information: ryan.lakin.md@gmail.com